7 results about "Corneal neovascularization" patented technology

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

This invention discloses siRNAs that target and inhibit ZEB1 gene expression and their applications, belonging to the field of biomedical technology. The siRNAs designed in this invention that target and inhibit ZEB1 gene expression include siRNA1-2913, siRNA2-652, and siRNA3-1073. The sense and antisense strands of siRNA1-2913 are shown in SEQ ID NO:1-2, the sense and antisense strands of siRNA2-652 are shown in SEQ ID NO:3-4, and the sense and antisense strands of siRNA3-1073 are shown in SEQ ID NO:5-6. These siRNAs can efficiently inhibit ZEB1 gene expression, inhibit the proliferation and migration of vascular endothelial cells, and intervene in the formation of pathological corneal neovascularization. They can be used for research on the pathogenesis and intervention of corneal neovascularization, showing very promising application prospects.

The invention discloses a corneal neovascularization automatic quantitative analysis and grading method, system and terminal based on image processing. The problems that in the existing corneal neovascularization evaluation process, a complete automatic technical system from image input, blood vessel segmentation to clinical quantitative scoring is lacked, a large amount of manual intervention is needed in the actual process, and high-efficiency and standardized automatic evaluation cannot be achieved are mainly solved. The invention provides a corneal neovascularization automatic quantitative analysis and grading method, system and terminal based on image processing, and provides a set of end-to-end automatic analysis system to realize a complete process of automatic CoNV segmentation, quantitative analysis and clinical structured scoring, so that the objectivity, consistency and efficiency of CoNV evaluation can be effectively improved, and the method and system are suitable for popularization and application. The obvious clinical application value and popularization potential are realized.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The invention provides application of an NCOA3 polyQ structural domain in preparation of a medicine for relieving ocular vascular abnormal hyperplasia diseases, relates to the technical field of biomedicine, and aims to solve the problems that in the prior art, an ocular pathological angiogenesis mechanism is complex, and safe and effective targeted intervention means are lacked. The construction of a mouse corneal micropocket pathological angiogenesis model proves that Nco3polyQ structural domain deletion can significantly inhibit corneal neovascularization: compared with a WT mouse, the Nco3wt / Q mouse corneal tissue CD31 positive signal is reduced, the number of corneal neovascularization in the Nco3Q / Q mouse is minimum, and the CD31 positive area is minimum; meanwhile, qPCR (quantitative polymerase chain reaction) detection of corneal tissues shows that mRNA (messenger ribonucleic acid) expression of the vascular marker genes Pecam1 and Cdh5 is in a decreasing trend and is further decreased in an Nco3Q / Q mouse. On the basis, the intervention strategy aiming at the NCOA3 polyQ structural domain is used for preparing the medicine for relieving the abnormal hyperplasia diseases of the ocular blood vessels, and a new treatment strategy and a potential target are provided for related diseases of the ophthalmology department.

The invention relates to application of a TWEAK-TWEAKR signal channel as a target spot in preparation of a medicine for treating corneal injury, and belongs to the technical field of biology. According to the invention, a TWEAK-TWEAKR signal channel is utilized, and in corneal injury, the blocking drug of the signal channel is adopted to block the TWEAK-TWEAKR signal channel, so that abnormal expression of related genes after corneal injury can be inhibited, corneal inflammatory response and corneal neovascularization can be inhibited, and corneal injury can be effectively treated.